{
  "$schema": "folio-library-entry/v1",
  "id": "10665-222160",
  "blocks": [
    {
      "id": "library/10665-222160/blocks/figure-img-p001-2",
      "types": [
        "folio-assistant-core:Figure",
        "doco:Figure"
      ],
      "kind": "figure",
      "title": "",
      "pageStart": 1,
      "pageEnd": 1,
      "target": "../images/img-p001-2.webp",
      "narrative": "draft",
      "content": "Full-page scan of the bilingual English/French first page of the Weekly Epidemiological Record, No. 43, 27 October 1978, with the WHO emblem in the masthead. It carries the article 'Meningococcal polysaccharide vaccines / Vaccins antiméningococciques polyosidiques' on the United States in two columns, and a box listing the epidemiological notes in the issue.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-222160/blocks/prose-page-001",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Page 1",
      "pageStart": 1,
      "pageEnd": 1,
      "target": "../sections/page-001.md",
      "narrative": null,
      "content": "MENINGOCOCCAL POLYSACCHARIDE VACCINES\nU nited States of A merica. — Polysaccharide vaccines against \ndiseases caused by Neisseria meningitidis serogroups A and C are \nnow licensed in the United States. They are prepared as monovalent \nand as bivalent antigens. The purpose of this statement is to \nsummarize available information on these antigens and to offer \ngeneral guidance regarding their role in the control of epidemics of \nmeningococcal disease in the civilian population of the United \nStates.\nMeningococcal disease is endemic in the United States and \nthroughout the world.1 \nIt caused ser",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Opens a bilingual Weekly Epidemiological Record statement on meningococcal polysaccharide vaccines newly licensed in the United States against serogroups A and C. It reviews the history of meningococcal epidemics, the decline of serogroup C disease in military recruits after routine vaccination, and the current serogroup and age distribution of cases. The page ends with the issue's table of contents.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-222160/blocks/prose-page-002",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Page 2",
      "pageStart": 2,
      "pageEnd": 2,
      "target": "../sections/page-002.md",
      "narrative": null,
      "content": "Wkly Epidem. Rec.: Mo. 43 - 27 Oct 197g\nRelevé epidem, hebd.' N° 43 - 27 OCL 197g\nThree meningococcal polysaccharide vaccines, monovalent A, \nmonovalent C, and bivalent A-C vaccine,* are licensed for selective \nuse in the United States. These vaccines are chemically defined \nantigens consisting of purified bacterial capsular polysaccharide, \neach inducing specific serogroup immunity. The duration of \nimmunity conferred by each vaccine is unknown.\nSerogroup A vaccine was evaluated in 62 000 Egyptian school- \nchildren 6-15 years old and appeared to be highly effective and not \nto induce any seri",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Continues the meningococcal vaccine statement, describing the monovalent A, monovalent C and bivalent vaccines, evidence of effectiveness from Egypt and Brazil, and poor effectiveness of serogroup C vaccine under two years. It advises against routine civilian vaccination but recommends use in serogroup A or C outbreaks, for some travellers and as an adjunct for household contacts, noting mild side effects and caution in pregnancy. A French version and notes on polyvalent vaccine development follow.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    }
  ]
}
